Entering text into the input field will update the search result below

Prometheus Biosciences initiates mid-stage PRA023 Crohn’s disease trial

Aug. 02, 2021 8:13 AM ETMerck & Co., Inc. (MRK) StockBy: SA News Team
  • Prometheus Biosciences (NASDAQ:RXDX) announces the initiation of the APOLLO-CD Phase 2a clinical trial evaluating PRA023 for moderate-to-severe Crohn’s disease (CD).
  • The trial is an open-label study designed to evaluate the proof-of-concept efficacy and safety of PRA023 in moderate-to-severe Crohn’s disease

Recommended For You

More Trending News

About MRK Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
MRK--
Merck & Co., Inc.